Patents by Inventor Heike S. Radeke
Heike S. Radeke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220339303Abstract: The present invention relates to systems, compositions, and methods for the synthesis and use of imaging agents, or precursors thereof. An imaging agent precursor may be converted to an imaging agent using the methods described herein. In some cases, the imaging agent is enriched in 18F. In some cases, an imaging agent may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs. In some embodiments, methods and compositions for assessing perfusion and innervation mismatch in a portion of a subject are provided.Type: ApplicationFiled: April 20, 2022Publication date: October 27, 2022Inventors: Heike S. Radeke, Richard R. Cesati, Ajay Purohit, Thomas D. Harris, Simon P. Robinson, Ming Yu, David S. Casebier, Carol Hui Hu, Matthias Broekema, David C. Onthank
-
Publication number: 20220288243Abstract: Novel compounds that find use as imaging agents within nuclear medicine applications (PET imaging) for imaging of cardiac innervation are disclosed. These PET based radiotracers may exhibit increased stability, decreased NE release (thereby reducing side effects), improved quantitative data, and/or high affinity for VMAT over prior radiotracers. Methods of using the compounds to image cardiac innervation are also provided. In some instances the compounds are developed by derivatizing certain compounds with 18F in a variety of positions: aryl, alkyl, a keto, benzylic, beta-alkylethers, gamma-propylalkylethers and beta-proplylalkylethers. Alternatively or additionally, a methyl group a is added to the amine, and/or the catechol functionality is either eliminated or masked as a way of making these compounds more stable.Type: ApplicationFiled: January 28, 2022Publication date: September 15, 2022Applicant: Lantheus Medical Imaging, Inc.Inventors: Ajay Purohit, Thomas D. Harris, Heike S. Radeke, Simon P. Robinson, Ming Yu, David S. Casebier, Michael T. Azure
-
Patent number: 11241509Abstract: Novel compounds that find use as imaging agents within nuclear medicine applications (PET imaging) for imaging of cardiac innervation are disclosed. These PET based radiotracers may exhibit increased stability, decreased NE release thereby reducing side effects, improved quantitative data, and/or high affinity for VMAT over prior radiotracers. In some instances the compounds are developed by derivatizing certain compounds with 18F in a variety of positions: aryl, alkyl, a keto, benzylic, beta-alkylethers, gamma-propylalkylethers and beta-proplylalkylethers. Alternatively or additionally, a methyl group a is added to the amine, and/or the catechol functionality is either eliminated or masked as a way of making these compounds more stable.Type: GrantFiled: May 22, 2018Date of Patent: February 8, 2022Assignee: Lantheus Medical Imaging, Inc.Inventors: Ajay Purohit, Thomas D. Harris, Heike S. Radeke, Simon P. Robinson, Ming Yu, David S. Casebier, Michael T. Azure
-
Publication number: 20220017459Abstract: The present invention generally relates to novel synthetic methods, systems, kits, salts, and precursors useful in medical imaging. In some embodiments, the present invention provides compositions comprising an imaging agent precursor, which may be formed using the synthetic methods described herein. An imaging agent may be converted to an imaging agent using the methods described herein. In some cases, the imaging agent is enriched in 18F. In some cases, an imaging agent including salt forms (e.g., ascorbate salt) may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs.Type: ApplicationFiled: July 28, 2021Publication date: January 20, 2022Applicant: Lantheus Medical Imaging, Inc.Inventors: Ajay Purohit, Pedro Benites, Heike S. Radeke, Joel Lazewatsky, L. Veronica Lee
-
Patent number: 11174223Abstract: The present invention generally relates to novel synthetic methods, systems, kits, salts, and precursors useful in medical imaging. In some embodiments, the present invention provides compositions comprising an imaging agent precursor, which may be formed using the synthetic methods described herein. An imaging agent may be converted to an imaging agent using the methods described herein. In some cases, the imaging agent is enriched in 18F. In some cases, an imaging agent including salt forms (e.g., ascorbate salt) may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs.Type: GrantFiled: May 12, 2017Date of Patent: November 16, 2021Assignee: Lantheus Medical Imaging, Inc.Inventors: Ajay Purohit, Pedro Benites, Heike S. Radeke, Joel Lazewatsky, L. Veronica Lee
-
Publication number: 20210300878Abstract: The present disclosure is directed, in part, to compounds and methods for imaging myocardial perfusion, comprising administering to a patient a contrast agent which comprises a compound that binds MC-1, and an imaging moiety, and scanning the patient using diagnostic imaging.Type: ApplicationFiled: December 4, 2020Publication date: September 30, 2021Applicant: Lantheus Medical Imaging, Inc.Inventors: David S. Casebier, Simon P. Robinson, Ajay Purohit, Heike S. Radeke, Michael T. Azure, Douglas D. Dischino
-
Patent number: 10889550Abstract: The present disclosure is directed, in part, to compounds and methods for imaging myocardial perfusion, comprising administering to a patient a contrast agent which comprises a compound that binds MC-1, and an imaging moiety, and scanning the patient using diagnostic imaging.Type: GrantFiled: September 27, 2018Date of Patent: January 12, 2021Assignee: Lantheus Medical Imaging, Inc.Inventors: David S. Casebier, Simon P. Robinson, Ajay Purohit, Heike S. Radeke, Michael T. Azure, Douglas D. Dischino
-
Publication number: 20200397927Abstract: The present invention relates to systems, compositions, and methods for the synthesis and use of imaging agents, or precursors thereof. An imaging agent precursor may be converted to an imaging agent using the methods described herein. In some cases, the imaging agent is enriched in 18F. In some cases, an imaging agent may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs. In some embodiments, methods and compositions for assessing perfusion and innervation mismatch in a portion of a subject are provided.Type: ApplicationFiled: March 24, 2020Publication date: December 24, 2020Applicant: Lantheus Medical Imaging, Inc.Inventors: Heike S. Radeke, Richard R. Cesati, Ajay Purohit, Thomas D. Harris, Simon P. Robinson, Ming Yu, David S. Casebier, Carol Hui Hu, Matthias Broekema, David C. Onthank
-
Publication number: 20200390912Abstract: The invention provides, in some embodiments, methods relating to assessing increased risk of developing atrial fibrillation (AF), and/or the likelihood of responding to particular AF therapies using imaging agents comprising an MMP inhibitor linked to an imaging moiety. The invention further provides methods for evaluating the presence of the risk of developing other cardiovascular conditions and assessing the effectiveness of treatment or other intervention for such conditions by determining MMP levels.Type: ApplicationFiled: May 22, 2020Publication date: December 17, 2020Applicants: Lantheus Medical Imaging, Inc., Yale UniversityInventors: Albert J. Sinusas, Joseph G. Akar, Richard R. Cesati, Heike S. Radeke, Stephen B. Haber
-
Publication number: 20200230264Abstract: The present invention provides compounds with imaging moieties for imaging a subject. The present invention also relates to systems, compositions, and methods for the synthesis and use of imaging agents, or precursors thereof. An imaging agent precursor may be converted to an imaging agent using the methods described herein. In some cases, a composition or plurality of imaging agents is enriched in 18F. In some cases, an imaging agent may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs.Type: ApplicationFiled: October 25, 2019Publication date: July 23, 2020Applicant: Lantheus Medical Imaging, Inc.Inventors: Richard R. Cesati, Heike S. Radeke, Suresh K. Pandey, Ajay Purohit, Simon P. Robinson
-
Patent number: 10500293Abstract: The present invention provides compounds with imaging moieties for imaging a subject. The present invention also relates to systems, compositions, and methods for the synthesis and use of imaging agents, or precursors thereof. An imaging agent precursor may be converted to an imaging agent using the methods described herein. In some cases, a composition or plurality of imaging agents is enriched in 18F. In some cases, an imaging agent may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs.Type: GrantFiled: January 31, 2018Date of Patent: December 10, 2019Assignee: Lantheus Medical Imaging, Inc.Inventors: Richard R. Cesati, Heike S. Radeke, Suresh K. Pandey, Ajay Purohit, Simon P. Robinson
-
Publication number: 20190127333Abstract: The present disclosure is directed, in part, to compounds and methods for imaging myocardial perfusion, comprising administering to a patient a contrast agent which comprises a compound that binds MC-1, and an imaging moiety, and scanning the patient using diagnostic imaging.Type: ApplicationFiled: September 27, 2018Publication date: May 2, 2019Applicant: Lantheus Medical Imaging, Inc.Inventors: David S. Casebier, Simon P. Robinson, Ajay Purohit, Heike S. Radeke, Michael T. Azure, Douglas D. Dischino
-
Publication number: 20180339070Abstract: Novel compounds that find use as imaging agents within nuclear medicine applications (PET imaging) for imaging of cardiac innervation are disclosed. These PET based radiotracers may exhibit increased stability, decreased NE release (thereby reducing side effects), improved quantitative data, and/or high affinity for VMAT over prior radiotracers. Methods of using the compounds to image cardiac innervation are also provided. In some instances the compounds are developed by derivatizing certain compounds with 18F in a variety of positions: aryl, alkyl, a keto, benzylic, beta-alkylethers, gamma-propylalkylethers and beta-proplylalkylethers. Alternatively or additionally, a methyl group a is added to the amine, and/or the catechol functionality is either eliminated or masked as a way of making these compounds more stable.Type: ApplicationFiled: May 22, 2018Publication date: November 29, 2018Applicant: Lantheus Medical Imaging, Inc.Inventors: Ajay Purohit, Thomas D. Harris, Heike S. Radeke, Simon P. Robinson, Ming Yu, David S. Casebier, Michael T. Azure
-
Patent number: 10125106Abstract: The present disclosure is directed, in part, to compounds and methods for imaging myocardial perfusion, comprising administering to a patient a contrast agent which comprises a compound that binds MC-1, and an imaging moiety, and scanning the patient using diagnostic imaging.Type: GrantFiled: June 21, 2017Date of Patent: November 13, 2018Assignee: Lantheus Medical Imaging, Inc.Inventors: David S. Casebier, Ajay Purohit, Heike S. Radeke
-
Publication number: 20180318456Abstract: The present invention provides compounds with imaging moieties for imaging a subject. The present invention also relates to systems, compositions, and methods for the synthesis and use of imaging agents, or precursors thereof. An imaging agent precursor may be converted to an imaging agent using the methods described herein. In some cases, a composition or plurality of imaging agents is enriched in 18F. In some cases, an imaging agent may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs.Type: ApplicationFiled: January 31, 2018Publication date: November 8, 2018Applicant: Lantheus Medical Imaging, Inc.Inventors: Richard R. Cesati, Heike S. Radeke, Suresh K. Pandey, Ajay Purohit, Simon P. Robinson
-
Patent number: 10022462Abstract: The present invention generally relates to methods and system for the synthesis of imaging agents, and precursors thereof. The methods may exhibit improved yields and may allow for the large-scale synthesis of imaging agents, including imaging agents comprising a radioisotope (e.g., 18F). Various embodiments of the invention may be useful as sensors, diagnostic tools, and the like. In some cases, methods for evaluating perfusion, including myocardial perfusion, are provided. Synthetic methods of the invention have also been incorporated into an automated synthesis unit to prepare and purify imaging agents that comprise a radioisotope. In some embodiments, the present invention provides a novel methods and systems comprising imaging agent 1, including methods of imaging in a subject comprising administering a composition comprising imaging agent 1 to a subject by injection, infusion, or any other known method, and imaging the area of the subject wherein the event of interest is located.Type: GrantFiled: February 15, 2017Date of Patent: July 17, 2018Assignee: Lantheus Medical Imaging, Inc.Inventors: Richard R. Cesati, Edward H. Cheesman, Joel Lazewatsky, Heike S. Radeke, Enrico Mongeau, Dianne D. Zdankiewicz, Marybeth Devine
-
Patent number: 10010631Abstract: Novel compounds that find use as imaging agents within nuclear medicine applications (PET imaging) for imaging of cardiac innervation are disclosed. These PET based radiotracers may exhibit increased stability, decreased NE release (thereby reducing side effects), improved quantitative data, and/or high affinity for VMAT over prior radiotracers. Methods of using the compounds to image cardiac innervation are also provided. In some instances the compounds are developed by derivatizing certain compounds with 18F in a variety of positions: aryl, alkyl, a keto, benzylic, beta-alkylethers, gamma-propylalkylethers and beta-proplylalkylethers. Alternatively or additionally, a methyl group a is added to the amine, and/or the catechol functionality is either eliminated or masked as a way of making these compounds more stable.Type: GrantFiled: June 12, 2013Date of Patent: July 3, 2018Assignee: Lantheus Medical Imaging, Inc.Inventors: Ajay Purohit, Thomas D. Harris, Heike S. Radeke, Simon P. Robinson, Ming Yu, David S. Casebier, Michael T. Azure
-
Publication number: 20180177901Abstract: The invention provides, in some embodiments, methods relating to assessing increased risk of developing atrial fibrillation (AF), and/or the likelihood of responding to particular AF therapies using imaging agents comprising an MMP inhibitor linked to an imaging moiety. The invention further provides methods for evaluating the presence of the risk of developing other cardiovascular conditions and assessing the effectiveness of treatment or other intervention for such conditions by determining MMP levels.Type: ApplicationFiled: October 2, 2017Publication date: June 28, 2018Applicants: Lantheus Medical Imaging, Inc., Yale UniversityInventors: Albert J. Sinusas, Joseph G. Akar, Richard R. Cesati, Heike S. Radeke, Stephen B. Haber
-
Patent number: 9919064Abstract: The present invention provides compounds with imaging moieties for imaging a subject. The present invention also relates to systems, compositions, and methods for the synthesis and use of imaging agents, or precursors thereof. An imaging agent precursor may be converted to an imaging agent using the methods described herein. In some cases, a composition or plurality of imaging agents is enriched in 18F. In some cases, an imaging agent may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs.Type: GrantFiled: November 23, 2016Date of Patent: March 20, 2018Assignee: Lantheus Medical Imaging, Inc.Inventors: Richard R. Cesati, Heike S. Radeke, Suresh K. Pandey, Ajay Purohit, Simon P. Robinson
-
Publication number: 20180009763Abstract: The present disclosure is directed, in part, to compounds and methods for imaging myocardial perfusion, comprising administering to a patient a contrast agent which comprises a compound that binds MC-1, and an imaging moiety, and scanning the patient using diagnostic imaging.Type: ApplicationFiled: June 21, 2017Publication date: January 11, 2018Applicant: Lantheus Medical Imaging, Inc.Inventors: David S. Casebier, Ajay Purohit, Heike S. Radeke